



Cleave Biosciences to Participate in Special Session “New Drugs on the Horizon” at AACR Annual Meeting 2015

Burlingame, Calif. – April 16, 2015 – Scientists from Cleave Biosciences will be participating in the special session, “New Drugs on the Horizon,” at the American Association for Cancer Research Annual Meeting 2015 in Philadelphia, PA on Sunday, April 19, 2015 from 3:15pm to 5:15pm ET. Daniel Anderson, Ph.D., Cleave’s Director of Biology, will present new in vivo and mechanism of action study results for CB-5083, a first-in-class, oral inhibitor of p97, a critical enzyme that controls various aspects of protein homeostasis. P97 inhibition is a novel approach that has the potential to treat a wide range of cancers, including both solid tumors and hematologic malignancies.

“It’s an honor to be invited to participate in this AACR annual meeting session that examines novel anti-cancer agents currently in development. Cleave has demonstrated impressive activity with CB-5083 in a wide range of in vivo models for solid tumors and hematologic malignancies, and we’ve advanced our program in two Phase 1 clinical trials,” said Laura Shawver, Ph.D., Chief Executive Officer of Cleave Biosciences.

Cleave’s presentation will be available in the [“News”](#) section of the company’s website following the presentation at AACR.

American Association for Cancer Research Annual Meeting 2015

Session Title:	New Drugs on the Horizon 2
Cleave Presentation:	Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
Presentation Number:	DDT02-01 (abstract)
Session Type:	Drug Development Track: Special Session
Session Start/End Time:	Sunday, April 19, 2015, 3:15pm – 5:15pm ET
Location:	Room 204, Pennsylvania Convention Center
Session Description:	Advances in the understanding of the molecular basis of cancer have led to the identification of key pathways involved in tumor initiation and progression, and translating this innovative science into the next generation of therapeutic agents remains one of the major hurdles to meaningful improvements in cancer treatment. While clinical successes remain extremely challenging to achieve, increasing numbers of targeted agents are emerging through clinical trials and making differences in the lives of patients. This symposium will provide the first disclosure of several new clinical agents that continue the drive for successful targeted therapies.
Presenters:	Representatives from Cleave Biosciences, Eli Lilly and Company, Celgene Corp., Bayer Pharma AG, Constellation Pharmaceuticals, Seattle Genetics

About Cleave Biosciences



Biopharmaceutical company Cleave Biosciences is a pioneer in the discovery and development of drugs that target protein homeostasis systems and have the potential to transform the treatment of people with difficult to treat solid tumors and hematologic malignancies. The company is privately held and located in Burlingame, California. Information regarding Cleave's clinical trials for oncology drug candidate CB-5083, including enrolling centers, is available by visiting www.clinicaltrials.gov (identifier # [NCT02243917](https://clinicaltrials.gov/ct2/show/study/NCT02243917) solid tumors, or # [NCT02223598](https://clinicaltrials.gov/ct2/show/study/NCT02223598) multiple myeloma.) For additional information, visit www.cleavebio.com.

###

Contacts:

Laura Shawver, Ph.D.
Chief Executive Officer
Cleave Biosciences
(650) 443-3010
lshawver@cleavebio.com

Pam Lord
Canale Communications
(619) 849-6003
pam@canalecomm.com